Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice.

Literature DB >> 29695518

Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice.

Armin Ghobadi¹, Michael P Rettig¹, Matthew S Holt¹, Julie K Ritchey¹, Krista Kennerly¹, Ezhilarasi Chendamarai¹, Linda Eissenberg¹, John F DiPersio¹.

Abstract

Entities: Chemical Species

Mesh：

Substances：

Year: 2018 PMID： 29695518 PMCID： PMC5992866 DOI： 10.1182/blood-2017-10-811620

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

× No keyword cloud information.

7 in total

Review 1. Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4.

Authors: M P Rettig; G Ansstas; J F DiPersio
Journal: Leukemia Date: 2011-09-02 Impact factor: 11.528

2. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.

Authors: Shaji Kumar; Sergio Giralt; Edward A Stadtmauer; Jean L Harousseau; Antonio Palumbo; William Bensinger; Raymond L Comenzo; Suzanne Lentzsch; Nikhil Munshi; Ruben Niesvizky; Jesus San Miguel; Heinz Ludwig; Leif Bergsagel; Joan Blade; Sagar Lonial; Kenneth C Anderson; Patrizia Tosi; Pieter Sonneveld; Orhan Sezer; David Vesole; Michele Cavo; Hermann Einsele; Paul G Richardson; Brian G M Durie; S Vincent Rajkumar
Journal: Blood Date: 2009-06-26 Impact factor: 22.113

3. Bortezomib is a rapid mobilizer of hematopoietic stem cells in mice via modulation of the VCAM-1/VLA-4 axis.

Authors: Armin Ghobadi; Michael P Rettig; Matthew L Cooper; Matthew S Holt; Julie K Ritchey; Linda Eissenberg; John F DiPersio
Journal: Blood Date: 2014-10-23 Impact factor: 22.113

Review 4. The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.

Authors: Jason Brayer; Rachid Baz
Journal: Ther Adv Hematol Date: 2017-06-28

5. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.

Authors: Edmund C Lee; Michael Fitzgerald; Bret Bannerman; Jill Donelan; Kristen Bano; Jennifer Terkelsen; Daniel P Bradley; Ozlem Subakan; Matthew D Silva; Ray Liu; Michael Pickard; Zhi Li; Olga Tayber; Ping Li; Paul Hales; Mary Carsillo; Vishala T Neppalli; Allison J Berger; Erik Kupperman; Mark Manfredi; Joseph B Bolen; Brian Van Ness; Siegfried Janz
Journal: Clin Cancer Res Date: 2011-09-08 Impact factor: 12.531

Review 6. Improving stem cell mobilization strategies: future directions.

Authors: W Bensinger; J F DiPersio; J M McCarty
Journal: Bone Marrow Transplant Date: 2009-01-12 Impact factor: 5.483

7. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.

Authors: Erik Kupperman; Edmund C Lee; Yueying Cao; Bret Bannerman; Michael Fitzgerald; Allison Berger; Jie Yu; Yu Yang; Paul Hales; Frank Bruzzese; Jane Liu; Jonathan Blank; Khristofer Garcia; Christopher Tsu; Larry Dick; Paul Fleming; Li Yu; Mark Manfredi; Mark Rolfe; Joe Bolen
Journal: Cancer Res Date: 2010-02-16 Impact factor: 12.701

7 in total

4 in total

1. Comparison of the efficacy of hematopoietic stem cell mobilization regimens: a systematic review and network meta-analysis of preclinical studies.

Authors: Chengxin Luo; Li Wang; Guixian Wu; Xiangtao Huang; Yali Zhang; Yanni Ma; Mingling Xie; Yanni Sun; Yarui Huang; Zhen Huang; Qiuyue Song; Hui Li; Yu Hou; Xi Li; Shuangnian Xu; Jieping Chen
Journal: Stem Cell Res Ther Date: 2021-05-29 Impact factor: 6.832